TKELLEY on DSK3SPTVN1PROD with NOTICES

46438 Federal Register / Vol. 77, No. 150 / Friday, August 3, 2012 / Notices 

A Federal Reserve Bank of New York 

(Ivan Hurwitz, Vice President) 33 

Liberty Street, New York, New York 

10045–0001: 

1. Westpac Banking Corporation, 

Sydney, Australia, to engage de novo 

through Westpac Capital Markets LLC, 

New York, New York in securities 

brokerage and riskless principal 

transactions, pursuant to Sections 

225.28(b)(7)(i) and 225.28(b)(7)(ii) of 

Regulation Y. 

Board of Governors of the Federal Reserve 

System, July 30, 2012. 

Robert deV. Frierson, 

Deputy Secretary of the Board. 

[FR Doc. 2012–18933 Filed 8–2–12; 8:45 am] 

BILLING CODE 6210–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Final Effect of Designation of a Class 

of Employees for Addition to the 

Special Exposure Cohort 

AGENCY: National Institute for 

Occupational Safety and Health 

(NIOSH), Centers for Disease Control 

and Prevention, Department of Health 

and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: HHS gives notice concerning 

the final effect of the HHS decision to 

designate a class of employees from the 

Feed Materials Production Center in 

Fernald, Ohio, as an addition to the 

Special Exposure Cohort (SEC) under 

the Energy Employees Occupational 

Illness Compensation Program Act of 

2000. On June 27, 2012, as provided for 

under 42 U.S.C. 7384q(b), the Secretary 

of HHS designated the following class of 

employees as an addition to the SEC: 

All employees of DOE, its predecessor 

agencies, and their contractors, or 

subcontractors who worked at the Feed 

Materials Production Center (FMPC) in 

Fernald, Ohio, from January 1, 1968 through 

December 31, 1978, for a number of work 

days aggregating at least 250 work days, 

occurring either solely under this 

employment, or in combination with work 

days within the parameters established for 

one or more other classes of employees 

included in the Special Exposure Cohort. 

This designation became effective on 

July 27, 2012, as provided for under 42 

U.S.C. 7384l(14)(C). Hence, beginning 

on July 27, 2012, members of this class 

of employees, defined as reported in 

this notice, became members of the SEC. 

FOR FURTHER INFORMATION CONTACT: 

Stuart L. Hinnefeld, Director, Division 

of Compensation Analysis and Support, 

National Institute for Occupational 

Safety and Health (NIOSH), 4676 

Columbia Parkway, MS C–46, 

Cincinnati, OH 45226, Telephone 877– 

222–7570. Information requests can also 

be submitted by email to 

DCAS@CDC.GOV. 

John Howard, 

Director, National Institute for Occupational 

Safety and Health. 

[FR Doc. 2012–19045 Filed 8–2–12; 8:45 am] 

BILLING CODE 4163–19–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the Secretary 

Findings of Research Misconduct 

AGENCY: Office of the Secretary, HHS. 

ACTION: Notice. 

SUMMARY: Notice is hereby given that 

the Office of Research Integrity (ORI) 

has taken final action in the following 

case: 

Mepur H. Ravindranath, Ph.D., John 

Wayne Cancer Institute: Based on the 

report of an investigation conducted by 

the John Wayne Cancer Institute (JWCI) 

and additional analysis conducted by 

ORI in its oversight review, ORI found 

that Dr. Mepur H. Ravindranath, former 

Director of the Laboratory of 

Glycoimmunotheraphy, JWCI, engaged 

in research misconduct in research 

supported by National Cancer Institute 

(NCI), National Institutes of Health 

(NIH), awards R21 CA107316 and R03 

CA107831. 

ORI found that the Respondent 

engaged in research misconduct by 

falsifying results reported for research 

supported by U.S. Public Health Service 

(PHS) grants R21 CA107316 and R03 

CA107831, in progress reports for those 

grants and in two publications in 

scientific journals. 

It is expressly understood that by 

entering into a Voluntary Settlement 

Agreement (Agreement), Respondent is 

not admitting to any of the allegations 

made against him by JWCI and/or ORI, 

or any of their respective agents, 

employees, associates, or related 

persons, including but not limited to the 

findings made by ORI listed in the 

Agreement. Respondent agreed to enter 

into the Agreement and not to contest 

the findings contained therein solely 

because contesting the findings would 

cause Respondent undue financial 

hardship and stress, and Respondent 

wished to seek finality. 

Specifically 

1. Respondent falsified the number of 

subjects accrued in the double-blind 

study reported in the paper 

Ravindranath, M.H., Muthugounder, S., 

Presser, N., Ye, X., Brosman, S., & 

Morton, D.L. ‘‘Endogenous immune 

response to gangliosides in patients 

with confined prostate cancer.’’ Int. J. 

Cancer 166:368–377, 2005 

(subsequently referred to as the ‘‘IJC 

paper) and later reviewed in 

Ravindranath, M.H. Yesowitch, P., 

Sumobay, C., & Morton, D.L. 

‘‘Glycoimmunomics of human cancer: 

Current concepts and future 

perspectives.’’ Future Oncology 

3(2):201–214, 2007 (subsequently 

referred to as the ‘‘Future Oncology 

paper’’), by reporting data of 7 of 63 

patients with serial bleeds taken at 

different points in time and reporting 

that the values from the 7 patients were 

for different patients. This same 

reporting data of individual patients 

with serial bleeds taken at different 

points in time and reporting that those 

values were for different patients was 

presented in the CA107316 and 

CA107831 final reports. 

2. The methodology used for the 

Tables of ANOVA results comparing 

Log Titers of IgM antibodies for the 

different subject groups in the IJC and 

Future Oncology papers and the 

CA107316 and CA107831 final reports 

is incorrect and false, since the papers 

and reports fail to state that the results 

are not for a simple ANOVA but include 

various degrees of repeated measures on 

the variables. 

3. In Table 1 of the CA107831 Final 

Report, Respondent reported mean log 

titer values for GM1b for healthy, BHP, 

and T3/4 CaP patients. These values 

exactly matched with values published 

for a different ganglioside, GM1, for 

healthy, BHP, and T3/4 CaP patients, 

earlier in the IJC (Table II) and Future 

Oncology publications. The only 

exception was the log titer value for T1/ 

2 CaP patients for GM1b (n = 20), which 

matched with the earlier published 

mean log titer value for GT1b (6.22 ± 

1.40; n = 36). ORI finds the pairwisedifference in the log titer values of 

GM1b between the T1/2 CaP and 

healthy patients, claimed to be 

significant (p<0.01), to therefore be 

incorrect and false. Respondent 

contends otherwise. 

4. Because Respondent included 

serial bleed values from individual 

patients in Table 1 of the IJC paper, the 

summary data for anti-ganglioside 

antibody values, and the statistical 

analyses derived from them in Tables II 

and III of the IJC paper, Tables 1 and 2 

of the Future Oncology paper, published 

Tables A and B of the CA107316 final 

report, and Tables 1 and 2B of the 

CA107831 final report are incorrect and 

false. The inclusion of serial bleeds from